Now Playing:
Artisan Partners Global Equity Team members discuss how the identification of major de-risking events in biopharma can help put risk/reward in their favor.

This video recording should be reviewed in conjunction with the accompanying slide presentation, which contains fund performance, portfolio holdings and other important information. Access “Slides” to view.

This investor update represents the views and opinions of Global Equity Team Business Leader Jamie Sandison and Analyst Navdeep Singh as of 25 Feb 2022, which are based on current market conditions, will fluctuate, and are subject to change without notice. While the information contained herein is believed to be reliable, there is no guarantee to the accuracy or completeness of any statement in the discussion. This material is for informational purposes only and should not be considered as investment advice or a recommendation of any investment service, product or individual security. Any forecasts contained herein are for illustrative purposes only and are not to be relied upon as advice or interpreted as a recommendation.

Compound Annual Growth Rate (CAGR) represents compound annual growth rate, the year-over-year growth rate over a specified period of time. It is calculated by taking the nth root of the total percentage growth rate, where n is the number of years in the period being considered.

NASDAQ Biotech Index: The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. Industry Classification Benchmark (ICB) is a comprehensive and rules based, transparent classification methodology based on research and market trends designed to support investment solutions. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. The index(es) are unmanaged; include net reinvested dividends; do not reflect fees or expenses; and are not available for direct investment.

For the purpose of determining the portfolio’s holdings, securities of the same issuer are aggregated to determine the weight in the Strategy. The holdings mentioned above comprised the following percentages of a representative account within the Artisan Global Equity Composite’s total net assets as of 31 Dec 2021: Deutsche Post AG 2.8%, Argenx SE 2.5%, Horizon Therapeutics PLC 1.9%, UCB SA 1.8%, Linde 0.8%. Portfolio holdings are subject to change without notice and are not intended as recommendations of individual securities. Securities mentioned, but not listed in the slide presentation are not held in the Fund as of the date of this report. This discussion is not intended to be a recommendation of any individual security.

Past performance does not guarantee future results. Current and future holdings are subject to risk.